Characteristics and course of patients treated with Kampo Medicine in the Department of General Medicine.
Japan
Kampo medicine
characteristics
general medicine
herbal medicine
Journal
Journal of general and family medicine
ISSN: 2189-7948
Titre abrégé: J Gen Fam Med
Pays: Japan
ID NLM: 101689875
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
22
08
2019
revised:
29
10
2019
accepted:
08
12
2019
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
epublish
Résumé
A recent investigation reported that 92.7% Japanese family physicians have prescribed Kampo medicine (KM). KM can treat a wide variety of conditions from mental disorders to physical weaknesses. However, the characteristics and course of patients treated with KM at the Department of General Medicine remain unclear. To investigate the characteristics and course of patients treated with KM in our hospital. Data on medical history, complaints, course after Kampo treatment, and Hamilton Depression Rating Scale (HAM-D) scores were retrogradely collected. The background of patients who received Kampo treatment was compared to that of patients who did not. Of 362 patients, 51 were treated with KM. Symptoms for which KM was prescribed included pain, general malaise, or sensory disturbance of extremities. All patients treated with KM were screened and initially diagnosed with a functional disorder or noncritical condition. KM including a crude drug of Most complaints of the patients treated with KM were pain, general malaise, and sensory disturbance. KM is more likely to be prescribed in patients with health-related anxiety or a history of mental disorders.
Sections du résumé
BACKGROUND
BACKGROUND
A recent investigation reported that 92.7% Japanese family physicians have prescribed Kampo medicine (KM). KM can treat a wide variety of conditions from mental disorders to physical weaknesses. However, the characteristics and course of patients treated with KM at the Department of General Medicine remain unclear.
AIMS
OBJECTIVE
To investigate the characteristics and course of patients treated with KM in our hospital.
METHODS
METHODS
Data on medical history, complaints, course after Kampo treatment, and Hamilton Depression Rating Scale (HAM-D) scores were retrogradely collected. The background of patients who received Kampo treatment was compared to that of patients who did not.
RESULT
RESULTS
Of 362 patients, 51 were treated with KM. Symptoms for which KM was prescribed included pain, general malaise, or sensory disturbance of extremities. All patients treated with KM were screened and initially diagnosed with a functional disorder or noncritical condition. KM including a crude drug of
CONCLUSION
CONCLUSIONS
Most complaints of the patients treated with KM were pain, general malaise, and sensory disturbance. KM is more likely to be prescribed in patients with health-related anxiety or a history of mental disorders.
Identifiants
pubmed: 32489756
doi: 10.1002/jgf2.294
pii: JGF2294
pmc: PMC7260161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48-55Informations de copyright
© 2020 The Authors. Journal of General and Family Medicine published by John Wiley & Sons Australia, Ltd on behalf of Japan Primary Care Association.
Déclaration de conflit d'intérêts
Takayama S., Kikuchi A., Ohsawa M., and Ishii T are members of the Department of Kampo Medicine, Tohoku University Graduate School of Medicine, which has a joint research collaboration with Tsumura & Co. (Tokyo, Japan).The other authors have stated explicitly that there are no conflicts of interest in connection with this article.
Références
Cell Mol Neurobiol. 2011 Nov;31(8):1203-12
pubmed: 21691759
J Pharm Pharmacol. 2009 Sep;61(9):1249-56
pubmed: 19703376
J Ethnopharmacol. 2015 May 26;166:23-30
pubmed: 25732836
EPMA J. 2014 Jun 27;5(1):10
pubmed: 25057332
Evid Based Complement Alternat Med. 2015;2015:726471
pubmed: 26681968
Evid Based Complement Alternat Med. 2011;2011:264289
pubmed: 21584269
Int J Chron Obstruct Pulmon Dis. 2018 Dec 27;14:129-139
pubmed: 30643399
Front Nutr. 2018 Jul 23;5:66
pubmed: 30083536
Neurochem Int. 2008 Dec;53(6-8):230-5
pubmed: 18755231
Nutr Neurosci. 2008 Feb;11(1):41-6
pubmed: 18510802
Evid Based Complement Alternat Med. 2019 Sep 2;2019:9590260
pubmed: 31565066
J Ethnopharmacol. 2011 Mar 8;134(1):74-81
pubmed: 21130853
Eur J Pharmacol. 2010 Jan 25;626(2-3):154-8
pubmed: 19818347
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1516-20
pubmed: 18558456
Geriatr Gerontol Int. 2017 May;17(5):679-688
pubmed: 27273639
Geriatr Gerontol Int. 2016 Sep;16(9):983-1001
pubmed: 27594406
J Ethnopharmacol. 2010 Feb 3;127(2):306-12
pubmed: 19913081
J Am Geriatr Soc. 2009 Jan;57(1):169-70
pubmed: 19170793
PLoS One. 2014 Dec 31;9(12):e116275
pubmed: 25551766
Evid Based Complement Alternat Med. 2015;2015:817616
pubmed: 26495025
Neuroscience. 2012 Apr 5;207:124-36
pubmed: 22314317
Neuroscience. 2009 Apr 10;159(4):1397-407
pubmed: 19409210
Intern Med. 2020 Jan 15;59(2):297-300
pubmed: 31534083
Int J Gynaecol Obstet. 2019 May;145(2):182-186
pubmed: 30734286
Evid Based Complement Alternat Med. 2018 Apr 29;2018:8620198
pubmed: 29853976